INTERIM REPORT FOR Q2 2022/23 AND THE HALF-YEAR - Seite 3

Q2 2022/23 CONFERENCE CALL

A conference call is scheduled for 3 May 2023, at 09:00-10:00 (CEST). The conference is broadcast live via Ambu.com/webcastQ22023.

To ask questions during the Q&A session, please register prior to the call via Ambu.com//conferencecallQ22023register.

Upon registration, you will receive dedicated dial-in details via e-mail to access the call, including a passcode, a unique PIN, dial-in numbers and a calendar invitation.

The investor presentation can be downloaded from Ambu.com/presentations.

Ambu A/S
Baltorpbakken 13
2750 Ballerup
Denmark
Tel. [phone]
CVR no.: 63 64 49 19
www.Ambu.com

CONTACT

Investors
Nicolai Thomsen
Director, Investor Relations & Strategic Finance
[e-mail]
[phone]

Media
Tine Bjørn Schmidt
Head of Corporate Communications
[e-mail]
[phone]

ABOUT AMBU
Ever since 1937, Ambu has been rethinking medical solutions to save lives and improve patient care. Millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia, and patient monitoring solutions. Today, we continue to collaborate with leading medical experts to deliver innovations that make a real difference to healthcare professionals and their patients.

At our headquarters in Copenhagen, Denmark, and around the world in Europe, North America and the Asia Pacific, 4,500+ team members keep Ambu moving forward. For more information, please visit Ambu.com.

Attachment

• Q2 and half-year company announcement no 9 2022-23